SCHEMBL2435352

SCHEMBL2435352

COC(=O)Cc1nn2c(c1C(=O)OC)CCCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.41
▸ MAPK1 P28482 2/20 0.40
▸ KMT2A Q03164 3/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ LMNA P02545 2/20 0.34
▸ HTT P42858 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ CNR2 P34972 1/20 0.33
▸ PRMT1 Q99873 2/20 0.33
▸ PRMT6 Q96LA8 1/20 0.33
▸ ABCC1 P33527 1/20 0.32
▸ RXFP1 Q9HBX9 2/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ HPGD P15428 2/20 0.32
▸ MAPT P10636 2/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2436166 0.89 ALDH1A1 (0.33) ALDH1A1MAPK1KMT2AMEN1PRMT1
SCHEMBL31053388 0.85 ALDH1A1 (0.42) ALDH1A1MAPK1KMT2AMEN1LMNA
SCHEMBL31714739 0.77 ALDH1A1 (0.45) ALDH1A1MAPK1KMT2AMEN1LMNA
SCHEMBL23414986 0.77 ALDH1A1 (0.48) ALDH1A1MAPK1KMT2AMEN1LMNA
SCHEMBL29852457 0.76 ALDH1A1 (0.44) ALDH1A1MAPK1KMT2AMEN1LMNA
SCHEMBL30323375 0.73 MAPK1 (0.49) ALDH1A1MAPK1KMT2AMEN1LMNA
SCHEMBL31053394 0.72 HCAR2 (0.35) ALDH1A1MAPK1KMT2APRMT1PRMT6
SCHEMBL21081513 0.69 MAPK1 (0.46) ALDH1A1MAPK1KMT2AMEN1LMNA
SCHEMBL24173026 0.69 PRMT1 (0.33) PRMT1PRMT6NPSR1
SCHEMBL31066451 0.69 ALDH1A1 (0.39) ALDH1A1MAPK1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2547679-B1 2,3 DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.6]NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR PFIZER (US) 2015-11-04 — — EP disclosed
US-20140080756-A1 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES PFIZER INC. (US) 2014-03-20 — — US disclosed
US-8609680-B2 2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives PFIZER INC. (US) 2013-12-17 — — US disclosed
EP-2547679-A1 2,3 DIHYDRO-1H-INDEN-1-YL- 2,7-DIAZASPIRO [3.6]NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR Pfizer Inc. (US) 2013-01-23 — — EP disclosed
WO-2011114271-A1 2,3 DIHYDRO-1H-INDEN-1-YL- 2,7-DIAZASPIRO [3.6] NONANE DERIVATIVES AND THEIR USE AS ANTAGONISTS OR INVERSE AGONISTS OF THE GHRELIN RECEPTOR PFIZER INC. (US) 2011-09-22 — — WO disclosed
US-20110230461-A1 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES PFIZER INC. 2011-09-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140080756-A1 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5]NONANE DERIVATIVES GIPR, GLP1R, GHSR ALDH1A1 1706/4885MAPK1 915/4885KMT2A 2302/4885
US-20110230461-A1 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES GIPR, GLP1R, GHSR ALDH1A1 1611/4885MAPK1 922/4885KMT2A 2320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback